Pancreatic Cancer Research

ResearcherPeking UniversityActive in the last 2 years

Kai Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7233-5892; OpenAlex author ID A5086106181, A5122922233. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: 4 papers · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 13

  1. Chemotherapy-induced senescence promotes stroma stiffness and antioxidant adaptation to promote chemoresistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-026-75772-5↗
  2. Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics. Co-author DOI 10.1136/gutjnl-2025-335683↗
  3. Disruption of Super-Enhancers in Activated Pancreatic Stellate Cells Facilitates Chemotherapy and Immunotherapy in Pancreatic Cancer. First author DOI 10.1002/advs.202308637↗
  4. Hypoxia-induced epigenetic regulation of miR-485-3p promotes stemness and chemoresistance in pancreatic ductal adenocarcinoma via SLC7A11-mediated ferroptosis. Co-author DOI 10.1038/s41420-024-02035-x↗
  5. Single-cell RNA-seq reveals characteristics in tumor microenvironment of PDAC with MSI-H following neoadjuvant chemotherapy with anti-PD-1 therapy. Co-author DOI 10.1016/j.canlet.2023.216421↗
  6. Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing. Co-author DOI 10.1186/s12967-023-04051-4↗
  7. Single cell RNA-seq reveals the CCL5/SDC1 receptor-ligand interaction between T cells and tumor cells in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215834↗
  8. Development and validation of prognostic and diagnostic model for pancreatic ductal adenocarcinoma based on scRNA-seq and bulk-seq datasets. Co-author DOI 10.1093/hmg/ddab343↗
  9. Single Cell RNA-Seq Identifies Immune-Related Prognostic Model and Key Signature-SPP1 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/genes13101760↗
  10. Hypoxic pancreatic cancer derived exosomal miR-30b-5p promotes tumor angiogenesis by inhibiting GJA1 expression. Co-author DOI 10.7150/ijbs.67675↗
  11. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression. Co-author DOI 10.1016/j.ebiom.2021.103315↗
  12. The Role of Exosomes in Pancreatic Cancer From Bench to Clinical Application: An Updated Review. Co-author DOI 10.3389/fonc.2021.644358↗
  13. Pancreatic stellate cells derived exosomal miR-5703 promotes pancreatic cancer by downregulating CMTM4 and activating PI3K/Akt pathway. Co-author DOI 10.1016/j.canlet.2020.06.009↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaodong Tian · 11 shared papers, 2021–2026 · strength 2.13
  2. Yinmo Yang · 8 shared papers, 2021–2024 · strength 1.41
  3. Yongsu Ma · 4 shared papers, 2022–2026 · strength 0.82
  4. Yinmo Yang · 3 shared papers, 2024–2026 · strength 0.73
  5. Xinxin Liu · 2 shared papers, 2024–2026 · strength 0.46
  6. Long Di · 2 shared papers, 2022–2023 · strength 0.37
  7. Weikang Liu · 2 shared papers, 2021–2024 · strength 0.34
  8. Yinmo Yang · 2 shared papers, 2020–2023 · strength 0.32
  9. Marko Kornmann · 2 shared papers, 2020–2021 · strength 0.30
  10. Feng Wang · 2 shared papers, 2021–2022 · strength 0.30
  11. Huahu Guo · 2 shared papers, 2020–2021 · strength 0.27
  12. Mingzhe Li · 2 shared papers, 2020–2021 · strength 0.27
  13. Robert A. Anders · 1 shared paper, 2026 · strength 0.26
  14. Enkui Zhang · 1 shared paper, 2026 · strength 0.26
  15. Heng‐Chung Kung · 1 shared paper, 2026 · strength 0.26
  16. Pengfei Wu · 1 shared paper, 2026 · strength 0.26
  17. Jacquelyn W. Zimmerman · 1 shared paper, 2026 · strength 0.26
  18. Dongqi Li · 1 shared paper, 2024 · strength 0.20
  19. Chong Du · 1 shared paper, 2024 · strength 0.20
  20. Yazhou Wang · 1 shared paper, 2024 · strength 0.20
  21. Xiangyu Chu · 1 shared paper, 2024 · strength 0.20
  22. Guangjun Nie · 1 shared paper, 2024 · strength 0.20
  23. Lei Zheng · 1 shared paper, 2023 · strength 0.19
  24. Di Long · 1 shared paper, 2022 · strength 0.16
  25. Yazhou Wang · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.